Edesa Biotech, Inc. — Director's Dealing 2018

Oct 13, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stellar Biotechnologies, Inc. (SBOT)
CIK: 0001540159
Period of Report: 2018-10-12

Reporting Person: OAKES FRANK R. (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-12	Common Shares, without par value	S	3000	$1.31	Disposed	51924	Direct

Footnotes

F1: These shares were sold pursuant to a trading plan adopted by the reporting person in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2: The Issuer completed a 1-for-7 reverse share split of its common shares effective May 4, 2018. The amount stated reflects the post-split adjustment. Fractional shares resulting from the reverse share split were rounded to the nearest whole share.